TEAM

ROD REUM, CPA, CGA
EXECUTIVE CHAIRMAN, CEO
Mr. Reum has 38 years of senior executive leadership of both public and private companies. He has played a key role in management
of the financing of many enterprises up to CAD $1.3 billion dollars for one project. He has been an officer and director of several public companies assisting a number of them through the “going public” phase of their growth. He has also been instrumental in bringing several new technologies from the development stage to market in the alternative energy, military and law enforcement sectors.
NICOLETTE KEITH, CPA, CGA
CHIEF FINANCIAL OFFICER
Ms. Keith has been a Chief Financial Officer for private and public companies listed on the TSX Venture and the Frankfurt exchanges. In addition Ms. Keith held a senior accounting role for a public company listed on the New York Stock Exchange. Nicolette speaks three
languages fluently and has a passing knowledge of several others which has served her well in the area of international business. Nicolette will provide strong leadership in the areas of regulatory reporting, capital management and international financial reporting standards.
DR. KEN REARDON
CHIEF SCIENCE OFFICER
Dr. Reardon is Professor and Jud and Pat Harper Chair of Chemical and Biological Engineering and holds joint appointments in several other programs at Colorado State University, including Cell and Molecular Biology and Biomedical Engineering. His research combines sensor development, bioreactor analysis, systems biology, and applied microbiology and microbial ecology. Dr. Reardon received his B.S. degree from the University of Pennsylvania and his Ph.D. from Caltech, both in chemical engineering.
MIKE KAO, CPA, CGA
VP FINANCE
Mr. Kao is a partner of WDM Chartered Professional Accountants, a Vancouver-based firm with over 30 years experience. Mike is proficient with both personal and corporate accounting, providing client services such as business advisory, consultancy, accounting, and tax services. WDM is registered with the Canadian Public Accountability Board, (CPAB), and the U.S. Public Company Accounting Oversight Board, (PCAOB), requiring a commitment to maintain the highest standards of professional objectivity, audit quality, and technical excellence.

ADVISORS

DR. ARISTOBULO LOAIZA
ADVISOR, AGRICULTURE
Dr. Loaiza is the former Sr. Manager of BASF New Business. He is known as a natural leader who leverages systems thinking and networking to drive business results. He has extensive chemicals, biotechnology and commercial training with deep knowledge and a solid network in various value chains including Biotech, Ag, and Nutrition and Food Safety. Dr. Loaiza received his M.S. in Biolnorganic Chemistry from UCLA and his Ph.D. in chemistry/ biochemistry from Purdue University.
KEARA SAUBER
BUSINESS DEVELOPMENT ADVISOR
Ms. Sauber began her career at GSK in a top sales role while winning multiple awards for running a $20M+ per quarter territory while performing an analyst role while on a rotation. After working in the healthcare space, Keara joined a fintech specialty lender backed by Goldman Sachs as Vice President. As an executive at a fast growth fintech company, Keara built strategic partnerships with companies in various verticals to build proprietary lending solutions, helping businesses achieve their financial goals. In 2017, Keara and her team originated more than $50 million in capital needs.
DR. DAVID DANDY
SCIENTIFIC ADVISOR
Dr. Dandy has been with Colorado State University since 1992. Dr. Dandy’s research in diagnostics focuses on developing and implementing microfluidic solutions for passive and active mixing strategies, passive pumping, automated flow control in microfluidic networks, and microparticle concentration and separation. He holds a total of five US patents on two label free biosensing technologies, the first employing an integrated optical waveguide and the second an optical method based on enzymatic conversion of target analyte. He is currently Professor and Department Head of Chemical and Biological Engineering and has a joint appointment as Professor of Biomedical Engineering.
ROD TURNER
FINANCING ADVISOR
Mr. Turner is the CEO of Manhattan Street Capital specializing in Reg A+, Reg D and US STO advisory services. Rod was a senior executive for two IPOs to NASDAQ (Ashton Tate, Symantec). Built a VC firm and was an angel investor in Ask Jeeves, INFN, AMRS, eASIC, Bloom Energy. High energy strategic thinker. Engineer with skills in all areas of business. Rod is considered an expert and innovator and sought after speaker in the areas of Reg A+, Reg D financings.
MIRO CERNETIG
BRAND & COMMUNICATIONS ADVISOR
Mr. Cernetig is the founder of Catalytico He has build brands for companies and projects measured in the billions of dollars. An award winning journalist and filmmaker, Miro brings deep research and storytelling to brands and strategy, thanks to decades of travel throughout Canada, Asia, Europe and the United States. He has written for The Globe & Mail as bureau chief in Beijing, New York, Vancouver, Alberta and The Arctic. His writing has appeared in The International Herald Tribune, The Economist, and The Toronto Star, where he was Montreal bureau chief.
DR. CHUCK HENRY
SCIENTIFIC ADVISOR
Dr. Henry is a Professor of Chemistry with a joint appointment as Professor of Chemical and Biological Engineering. He served as Chair of the Department of Chemistry from 2014 2018. Dr. Henry has published over 180 peer reviewed publications and generated eight issued patents. current research includes projects to develop low cost capillary flow driven diagnostic assays and biosensors for
infectious diseases (bacterial and viral) and disease biomarkers, and the creation of new tissue on a chip systems that integrate living ex vivo tissue into microfluidic devices.
DR. BRIAN GEISS
SCIENTIFIC ADVISOR
Dr. Geiss is Associate Professor in Microbiology, Immunology, and Pathology at Colorado State University. Since 2005, he has studied RNA viruses including flaviviruses, alphaviruses, and coronaviruses. Dr. Geiss has been supported by the NIH since 2006 to develop novel antiviral targeting flavivirus RNA capping and define the mechanisms of viral RNA capping. He has focused on development of novel biosensors for the detection of infectious diseases, including pathogen nucleic acids, virus particles, intact bacterial cells, and
pathogen specific antibody responses in a variety of sample matrices.
ARNOLD PEINADO
BUSINESS DEVELOPMENT ADVISOR
Mr. Peinado is a retired partner of the international law firm of Milbank, Tweed, Hadley & McCloy. He was a senior partner in the Firm's Global Securities group and Transportation and Space Finance team. He joined the firm in 1982 having received a JD from Harvard Law School and an MBA Harvard Business School. He has been a member of the board of the UJC since 1995.and is also a
trustee of the New Jersey Chapter of The Nature Conservancy, a leading conservation and environmentally focused NGO; a director of iCivics, the largest provider of on line civic education in the US; and a director of the Alleluia Fund, the grants making arm of the Episcopal Diocese of Newark, N.J.

DIRECTORS

ROD REUM, CPA, CGA
Mr. Reum has 38 years of senior executive leadership of both public and private companies. He has played a key role in management
of the financing of many enterprises up to CAD $1.3 billion dollars for one project. He has been an officer and director of several public companies assisting a number of them through the “going public” phase of their growth. He has also been instrumental in bringing several new technologies from the development stage to market in the alternative energy, military and law enforcement sectors.
CYNTHIA EKBERG TSAI
Ms. Tsai is known for her unique skills in working with executives from companies that desire strategic advice and hands on experience in partnering, investment and brand building in the US, Europe, South America and Asia. Currently as CEO of Tana Systems, a global software and IT company based in the US and India. Tsai leads a team of 50 engineers in the US and 500 engineers in India. She is also the CEO of Healthquest , a global biotechnology and medical technologies advisory.
MICHAEL HARRISON
Mr. Harrison has 35 years of experience in investment banking with interests in resource, energy, and biotechnology sectors. He has served as CEO of two companies that he led to successful exits. He has been on the board of directors for numerous international publicly listed companies and has raised millions of dollars in funding for private and publicly traded companies.
DAVID SMALLEY
Mr. Smalley has nearly 30 years’ experience practicing corporate and securities law, providing legal services for financing private and
public companies. Mr. Smalley has been and continues to be a director of a number of capital pool companies listed for trading on the TSX Venture Exchange. He has served as director and officer of numerous public and private companies.
LARRY DOAN
Mr. Doan is a retired executive who was a director/founder and Vice President of Extreme CCTV (1999 2008), a company that he helped take public on the Toronto Stock Exchange and was part of the Directors committee that saw the takeover of the company in 2007. His focus had been on developing sales channels in North America and Europe.
Invest